<?xml version="1.0" encoding="UTF-8"?>
<results title="viral_systemic_diseases">
 <result pre="today. Treatment strategies against 2019-nCoV Developing neutralizing antibodies to 2019-nCoV" exact="Coronavirus" post="entry starts with the S protein binding to a"/>
 <result pre="are initial positive reports that lopinavir and ritonavir, which are" exact="HIV" post="protease inhibitors, have some clinical efficacy against 2019-nCoV, similar"/>
 <result pre="quickly, and a challenge to make sure that the mutating" exact="RNA virus" post="will not escape its neutralization. A cocktail antibody approach"/>
 <result pre="entry 41 , which is the same receptor that the" exact="SARS coronavirus" post="uses for entry 42 . For both viruses, the"/>
 <result pre="the viral membrane and cell membrane will occur. Subsequently, the" exact="RNA virus" post="will replicate its genome inside the cell, and ultimately"/>
 <result pre="to the human IgG1 domain (ACE2-NN-Ig) was effective in neutralizing" exact="SARS coronavirus" post="in vitro, with a 50% inhibitory concentration of 2"/>
 <result pre="was one of the early agents developed as a potential" exact="HIV" post="medication 67 . The protein contained the first two"/>
 <result pre="are known to bind gp120 on the surface of infected" exact="HIV" post="cells. CD4-IgG was shown to neutralize HIV in vitro,"/>
 <result pre="surface of infected HIV cells. CD4-IgG was shown to neutralize" exact="HIV" post="in vitro, preventing infection. The protein was also safe"/>
 <result pre="and giving even more potent neutralizing activity, essentially 100% of" exact="HIV" post="isolates and making rhesus macaques resistant to multiple simian-human"/>
 <result pre="to multiple simian-human immunodeficiency virus challenges 70, 71 . While" exact="HIV" post="and 2019-nCoV are very different viruses, with different cell"/>
 <result pre="cell types, kinetics, and clinical courses, the previous results with" exact="HIV" post="are encouraging that this could be a therapeutic strategy"/>
 <result pre="N Zhang D Wang W et al. : A Novel" exact="Coronavirus" post="from Patients with Pneumonia in China, 2019. N Engl"/>
 <result pre="ZY Wang Y Lau P et al. : Isolation of" exact="HCV" post="Neutralizing Antibodies by Yeast Display. Methods Mol Biol. 2019;"/>
 <result pre="al. : Repurposing of clinically developed drugs for treatment of" exact="Middle East respiratory syndrome" post="coronavirus infection. Antimicrob Agents Chemother. 2014; 58( 8): 4885–"/>
 <result pre=": Angiotensin-converting enzyme 2 is a functional receptor for the" exact="SARS coronavirus." post="Nature. 2003; 426( 6965): 450– 454. 10.1038/nature02145 14647384 43"/>
 <result pre="Breaking the convention: Sialoglycan variants, Co-receptors and Alternative Receptors for" exact="Influenza" post="A Virus Entry. J Virol. 2019; pii: JVI.01357-19. 10.1128/JVI.01357-19"/>
 <result pre="MJ et al. : A 193-amino acid fragment of the" exact="SARS coronavirus" post="S protein efficiently binds angiotensin-converting enzyme 2. J Biol"/>
 <result pre="F Li W Farzan M et al. : Structure of" exact="SARS coronavirus" post="spike receptor-binding domain complexed with receptor. Science. 2005; 309("/>
 <result pre=": Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected" exact="SARS coronavirus." post="Virology. 2014; 454–455: 157– 168. 10.1016/j.virol.2014.02.005 24725942 65 Glowacka"/>
 <result pre="immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric" exact="AIDS" post="Clinical Trials Group Protocol 351 Study Team. J Infect"/>
</results>
